JP2012501999A - ウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体 - Google Patents
ウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体 Download PDFInfo
- Publication number
- JP2012501999A JP2012501999A JP2011525532A JP2011525532A JP2012501999A JP 2012501999 A JP2012501999 A JP 2012501999A JP 2011525532 A JP2011525532 A JP 2011525532A JP 2011525532 A JP2011525532 A JP 2011525532A JP 2012501999 A JP2012501999 A JP 2012501999A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- ribofuranosyl
- pyrrolo
- amine
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003833 nucleoside derivatives Chemical class 0.000 title description 22
- 239000003112 inhibitor Substances 0.000 title description 20
- 230000003612 virological effect Effects 0.000 title description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 124
- 208000015181 infectious disease Diseases 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract 3
- -1 azido, ethynyl Chemical group 0.000 claims description 55
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 21
- 150000002431 hydrogen Chemical class 0.000 claims description 21
- 230000010076 replication Effects 0.000 claims description 21
- 239000002777 nucleoside Substances 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000000651 prodrug Substances 0.000 claims description 15
- 229940002612 prodrug Drugs 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 229910052757 nitrogen Chemical group 0.000 claims description 14
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 239000001226 triphosphate Substances 0.000 claims description 10
- 150000004712 monophosphates Chemical class 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 235000011178 triphosphate Nutrition 0.000 claims description 8
- CWPKRLBNQHXJQX-NZQZLILVSA-N (2r,3r,4r,5r)-2-[4-amino-5-(1h-pyrazol-5-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(C=2NN=CC=2)=C1 CWPKRLBNQHXJQX-NZQZLILVSA-N 0.000 claims description 7
- 235000011180 diphosphates Nutrition 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 125000006239 protecting group Chemical group 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000003835 nucleoside group Chemical group 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 239000001177 diphosphate Substances 0.000 claims description 5
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 5
- 125000006413 ring segment Chemical group 0.000 claims description 5
- XGBYBQNGOAAYCB-MVNCPAOLSA-N (2r,3r,4r,5r)-2-[4-amino-5-(1,3,4-oxadiazol-2-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(C=2OC=NN=2)=C1 XGBYBQNGOAAYCB-MVNCPAOLSA-N 0.000 claims description 4
- SPKMOPYEWVIJRT-FTTKWNSESA-N (2r,3r,4r,5r)-2-[4-amino-5-(1,3-oxazol-2-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(C=2OC=CN=2)=C1 SPKMOPYEWVIJRT-FTTKWNSESA-N 0.000 claims description 4
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 4
- ZTVITMOPWSQHOC-JEGMJTAISA-N (2r,3r,4r,5r)-2-(4-amino-5-pyrimidin-2-ylpyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(C=2N=CC=CN=2)=C1 ZTVITMOPWSQHOC-JEGMJTAISA-N 0.000 claims description 3
- DMIYCUGFHZUNTP-YTUKDDMISA-N (2r,3r,4r,5r)-2-[4-amino-3-(1h-pyrazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(C2=NNC=C2)=N1 DMIYCUGFHZUNTP-YTUKDDMISA-N 0.000 claims description 3
- ISFKCFKKYCKEPL-MVNCPAOLSA-N (2r,3r,4r,5r)-2-[4-amino-5-(1,2,4-oxadiazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(C2=NOC=N2)=C1 ISFKCFKKYCKEPL-MVNCPAOLSA-N 0.000 claims description 3
- URLTYTZIZXJZKO-NZQZLILVSA-N (2r,3r,4r,5r)-2-[4-amino-5-(1h-pyrazol-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(C2=CNN=C2)=C1 URLTYTZIZXJZKO-NZQZLILVSA-N 0.000 claims description 3
- FIJJPTBHOUONSJ-MVNCPAOLSA-N (2r,3r,4r,5r)-5-[4-amino-5-(1,2,4-oxadiazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-4-fluoro-2-(hydroxymethyl)-4-methyloxolan-3-ol Chemical compound C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(C2=NOC=N2)=C1 FIJJPTBHOUONSJ-MVNCPAOLSA-N 0.000 claims description 3
- GBQGCDKSTDXOAT-FTTKWNSESA-N (2r,3r,4r,5r)-5-[4-amino-5-(1,3-oxazol-2-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-4-fluoro-2-(hydroxymethyl)-4-methyloxolan-3-ol Chemical class C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(C=2OC=CN=2)=C1 GBQGCDKSTDXOAT-FTTKWNSESA-N 0.000 claims description 3
- SOKHFWGXMBUNEN-NZQZLILVSA-N (2r,3r,4r,5r)-5-[4-amino-5-(1h-pyrazol-5-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-4-fluoro-2-(hydroxymethyl)-4-methyloxolan-3-ol Chemical compound C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(C=2NN=CC=2)=C1 SOKHFWGXMBUNEN-NZQZLILVSA-N 0.000 claims description 3
- BZWMWQFIWRMQMN-JEGMJTAISA-N [[(2r,3r,4r,5r)-5-(4-amino-5-pyrimidin-2-ylpyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C2=NC=NC(N)=C2C(C=2N=CC=CN=2)=C1 BZWMWQFIWRMQMN-JEGMJTAISA-N 0.000 claims description 3
- VJHWYADEBDQBGR-MVNCPAOLSA-N [[(2r,3r,4r,5r)-5-[4-amino-5-(1,2,4-oxadiazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C2=NC=NC(N)=C2C(C2=NOC=N2)=C1 VJHWYADEBDQBGR-MVNCPAOLSA-N 0.000 claims description 3
- GMPMEXVZIFVRGY-MVNCPAOLSA-N [[(2r,3r,4r,5r)-5-[4-amino-5-(1,2,4-oxadiazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(F)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C2=NC=NC(N)=C2C(C2=NOC=N2)=C1 GMPMEXVZIFVRGY-MVNCPAOLSA-N 0.000 claims description 3
- SGRVFTIOERMWDP-MVNCPAOLSA-N [[(2r,3r,4r,5r)-5-[4-amino-5-(1,3,4-oxadiazol-2-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C2=NC=NC(N)=C2C(C=2OC=NN=2)=C1 SGRVFTIOERMWDP-MVNCPAOLSA-N 0.000 claims description 3
- AEPINTXRLQKNJJ-FTTKWNSESA-N [[(2r,3r,4r,5r)-5-[4-amino-5-(1,3-oxazol-2-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C2=NC=NC(N)=C2C(C=2OC=CN=2)=C1 AEPINTXRLQKNJJ-FTTKWNSESA-N 0.000 claims description 3
- HRFLMJJWGUZBBL-FTTKWNSESA-N [[(2r,3r,4r,5r)-5-[4-amino-5-(1,3-oxazol-2-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(F)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C2=NC=NC(N)=C2C(C=2OC=CN=2)=C1 HRFLMJJWGUZBBL-FTTKWNSESA-N 0.000 claims description 3
- YCHHGZUVCZIMKX-MVNCPAOLSA-N [[(2r,3r,4r,5r)-5-[4-amino-5-(1-methyltetrazol-5-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical class CN1N=NN=C1C(C1=C(N)N=CN=C11)=CN1[C@H]1[C@@](O)(C)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 YCHHGZUVCZIMKX-MVNCPAOLSA-N 0.000 claims description 3
- PUGHEWJIGPUKAH-NZQZLILVSA-N [[(2r,3r,4r,5r)-5-[4-amino-5-(1-methyltriazol-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1=NN(C)C=C1C(C1=C(N)N=CN=C11)=CN1[C@H]1[C@@](O)(C)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PUGHEWJIGPUKAH-NZQZLILVSA-N 0.000 claims description 3
- PSHTYOIJYOSPGD-NZQZLILVSA-N [[(2r,3r,4r,5r)-5-[4-amino-5-(1h-pyrazol-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C2=NC=NC(N)=C2C(C2=CNN=C2)=C1 PSHTYOIJYOSPGD-NZQZLILVSA-N 0.000 claims description 3
- QBIHFKIFLHGTEO-NZQZLILVSA-N [[(2r,3r,4r,5r)-5-[4-amino-5-(1h-pyrazol-5-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C2=NC=NC(N)=C2C(C=2NN=CC=2)=C1 QBIHFKIFLHGTEO-NZQZLILVSA-N 0.000 claims description 3
- GBBBLCXMUJZZNH-NZQZLILVSA-N [[(2r,3r,4r,5r)-5-[4-amino-5-(1h-pyrazol-5-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(F)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C2=NC=NC(N)=C2C(C=2NN=CC=2)=C1 GBBBLCXMUJZZNH-NZQZLILVSA-N 0.000 claims description 3
- UCTADSGLDVTYQV-ROMFRFKVSA-N [[(2r,3r,4r,5r)-5-[4-amino-5-(2-methoxy-1,3-thiazol-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound S1C(OC)=NC(C=2C3=C(N)N=CN=C3N([C@H]3[C@]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O3)(C)O)C=2)=C1 UCTADSGLDVTYQV-ROMFRFKVSA-N 0.000 claims description 3
- DSOFSABMBDGOBT-MVNCPAOLSA-N [[(2r,3r,4r,5r)-5-[4-amino-5-(2-methyltetrazol-5-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical class CN1N=NC(C=2C3=C(N)N=CN=C3N([C@H]3[C@]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O3)(C)O)C=2)=N1 DSOFSABMBDGOBT-MVNCPAOLSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- YJAZFMYSZBPQEB-KHTZZEJVSA-N (2r,3r,4r,5r)-2-(4-amino-5-thiophen-2-ylpyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(C=2SC=CC=2)=C1 YJAZFMYSZBPQEB-KHTZZEJVSA-N 0.000 claims description 2
- BRXWRPCKVIKARN-NZQZLILVSA-N (2r,3r,4r,5r)-2-[4-amino-5-(1-methyltriazol-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound N1=NN(C)C=C1C(C1=C(N)N=CN=C11)=CN1[C@H]1[C@@](O)(C)[C@H](O)[C@@H](CO)O1 BRXWRPCKVIKARN-NZQZLILVSA-N 0.000 claims description 2
- IXTFYDIEECMIPI-ROMFRFKVSA-N (2r,3r,4r,5r)-2-[4-amino-5-(2-methoxy-1,3-thiazol-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound S1C(OC)=NC(C=2C3=C(N)N=CN=C3N([C@H]3[C@]([C@H](O)[C@@H](CO)O3)(C)O)C=2)=C1 IXTFYDIEECMIPI-ROMFRFKVSA-N 0.000 claims description 2
- CPMSDTBFYZHAHD-PDLPPMLWSA-N (2r,3r,4r,5r)-2-[4-amino-5-(6-methoxypyridin-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C1=NC(OC)=CC=C1C(C1=C(N)N=CN=C11)=CN1[C@H]1[C@@](O)(C)[C@H](O)[C@@H](CO)O1 CPMSDTBFYZHAHD-PDLPPMLWSA-N 0.000 claims description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 2
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims description 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- LYQJAYZAFGOUKW-RPNCAOPKSA-N C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C2=NC=NC(N)=C2C(C2=NNC=C2)=N1 Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C2=NC=NC(N)=C2C(C2=NNC=C2)=N1 LYQJAYZAFGOUKW-RPNCAOPKSA-N 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 description 74
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 63
- 238000005481 NMR spectroscopy Methods 0.000 description 53
- 239000000203 mixture Substances 0.000 description 50
- 230000001419 dependent effect Effects 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 31
- 230000029812 viral genome replication Effects 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 15
- 125000001424 substituent group Chemical group 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- 230000009385 viral infection Effects 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 108010047761 Interferon-alpha Proteins 0.000 description 13
- 102000006992 Interferon-alpha Human genes 0.000 description 13
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 238000004007 reversed phase HPLC Methods 0.000 description 13
- 229960000329 ribavirin Drugs 0.000 description 13
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- 241000710781 Flaviviridae Species 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 102000014150 Interferons Human genes 0.000 description 9
- 108010050904 Interferons Proteins 0.000 description 9
- 108060004795 Methyltransferase Proteins 0.000 description 9
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 229940079322 interferon Drugs 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 241000709664 Picornaviridae Species 0.000 description 8
- 208000036142 Viral infection Diseases 0.000 description 8
- 241001493065 dsRNA viruses Species 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 208000010710 hepatitis C virus infection Diseases 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- NEUWPDLMDVINSN-UHFFFAOYSA-N 1h-pyrazol-5-ylboronic acid Chemical compound OB(O)C=1C=CNN=1 NEUWPDLMDVINSN-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 101710144111 Non-structural protein 3 Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000003039 volatile agent Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 4
- 239000005973 Carvone Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000710842 Japanese encephalitis virus Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 208000009341 RNA Virus Infections Diseases 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 150000001793 charged compounds Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000006880 cross-coupling reaction Methods 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000002342 ribonucleoside Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229950006081 taribavirin Drugs 0.000 description 4
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 description 4
- VDPOJGOZLKLNFY-YUTYNTIBSA-N (2r,3r,4r,5r)-2-(4-amino-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(I)=C1 VDPOJGOZLKLNFY-YUTYNTIBSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000725619 Dengue virus Species 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- 241000991587 Enterovirus C Species 0.000 description 3
- 229940124772 HCV-NS5B polymerase inhibitor Drugs 0.000 description 3
- 241000709721 Hepatovirus A Species 0.000 description 3
- 102100040018 Interferon alpha-2 Human genes 0.000 description 3
- 108010079944 Interferon-alpha2b Proteins 0.000 description 3
- 101150116046 PCBD1 gene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 241000710886 West Nile virus Species 0.000 description 3
- 101100297580 Xenopus laevis pcbd gene Proteins 0.000 description 3
- 241000710772 Yellow fever virus Species 0.000 description 3
- XENHXZMAOSTXGD-DSMKLBDQSA-N [(2r,3r,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)-4-methyloxolan-3-yl] (2s)-2-amino-3-methylbutanoate;dihydrochloride Chemical compound Cl.Cl.C[C@@]1(O)[C@H](OC(=O)[C@@H](N)C(C)C)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 XENHXZMAOSTXGD-DSMKLBDQSA-N 0.000 description 3
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 150000002243 furanoses Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 229940051021 yellow-fever virus Drugs 0.000 description 3
- FRPQIYNSKIHXTD-MVNCPAOLSA-N (2r,3r,4r,5r)-2-[4-amino-5-(1-methyltetrazol-5-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound CN1N=NN=C1C(C1=C(N)N=CN=C11)=CN1[C@H]1[C@@](O)(C)[C@H](O)[C@@H](CO)O1 FRPQIYNSKIHXTD-MVNCPAOLSA-N 0.000 description 2
- WMFCXPIGBPKRGG-MVNCPAOLSA-N (2r,3r,4r,5r)-2-[4-amino-5-(2-methyltetrazol-5-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound CN1N=NC(C=2C3=C(N)N=CN=C3N([C@H]3[C@]([C@H](O)[C@@H](CO)O3)(C)O)C=2)=N1 WMFCXPIGBPKRGG-MVNCPAOLSA-N 0.000 description 2
- PVTGKZYFQUNBNM-YUTYNTIBSA-N (2r,3r,4r,5r)-5-(4-amino-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)-4-fluoro-2-(hydroxymethyl)-4-methyloxolan-3-ol Chemical compound C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(I)=C1 PVTGKZYFQUNBNM-YUTYNTIBSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 2
- 0 CC([C@](*)N*)=O Chemical compound CC([C@](*)N*)=O 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 101150003085 Pdcl gene Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108010078233 Thymalfasin Proteins 0.000 description 2
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 2
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- OSZLMCUIYDPWNI-UHFFFAOYSA-N hexyl(dimethyl)azanium;hydrogen carbonate Chemical compound OC([O-])=O.CCCCCC[NH+](C)C OSZLMCUIYDPWNI-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 235000013902 inosinic acid Nutrition 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940065638 intron a Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 150000002905 orthoesters Chemical class 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000004944 pyrrolopyrimidines Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 2
- 229960002218 sodium chlorite Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 2
- 229960004231 thymalfasin Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- YOWGRWHKDCHINP-UHFFFAOYSA-N tributyl(1,3-oxazol-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=NC=CO1 YOWGRWHKDCHINP-UHFFFAOYSA-N 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- KHPCBZYTDJCPHW-GITKWUPZSA-N (2r,3r,4r,5r)-2-(2,6-diaminopurin-9-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(N)=NC(N)=C2N=C1 KHPCBZYTDJCPHW-GITKWUPZSA-N 0.000 description 1
- YOAGQSGRMBEQCY-YUTYNTIBSA-N (2r,3r,4r,5r)-2-(4-amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(F)=C1 YOAGQSGRMBEQCY-YUTYNTIBSA-N 0.000 description 1
- KGJUMKNRILMXFE-GAJNKVMBSA-N (2r,3r,4r,5r)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,5-bis(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)CO KGJUMKNRILMXFE-GAJNKVMBSA-N 0.000 description 1
- PDSUZZBFTMLIAM-GAJNKVMBSA-N (2r,3r,4r,5r)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3-(fluoromethyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)CF PDSUZZBFTMLIAM-GAJNKVMBSA-N 0.000 description 1
- IRZRJANZDIOOIF-GAJNKVMBSA-N (2r,3r,4r,5r)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C=C1 IRZRJANZDIOOIF-GAJNKVMBSA-N 0.000 description 1
- PASOFFRBGIVJET-YRKGHMEHSA-N (2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 PASOFFRBGIVJET-YRKGHMEHSA-N 0.000 description 1
- YADGDYFXYUSMOO-CZTVAOSCSA-N (2r,3r,4r,5r)-2-[4-amino-5-(2h-tetrazol-5-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(C=2NN=NN=2)=C1 YADGDYFXYUSMOO-CZTVAOSCSA-N 0.000 description 1
- CVJKYIBHHRMLLJ-NRMKKVEVSA-N (2r,3r,4r,5r)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)-4-methoxy-4-methyloxolan-3-ol Chemical compound CO[C@]1(C)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C=C1 CVJKYIBHHRMLLJ-NRMKKVEVSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IKKSFNXOAHQCFQ-UHFFFAOYSA-N ({[(14-cyclohexyl-3-methoxy-6-methyl-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocin-11-yl)carbonyl]amino}sulfonyl)acetic acid Chemical compound C12=CC=C(C(=O)NS(=O)(=O)CC(O)=O)C=C2N2CCN(C)CC3=CC(OC)=CC=C3C2=C1C1CCCCC1 IKKSFNXOAHQCFQ-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- NBKORJKMMVZAOZ-VPCXQMTMSA-N 1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 NBKORJKMMVZAOZ-VPCXQMTMSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- YVPUSKFBJNVTFX-UHFFFAOYSA-N 13-cyclohexyl-6-oxo-5,7-dihydroindolo[1,2-d][1,4]benzodiazepine-10-carboxylic acid Chemical compound C=12C3=CC=CC=C3NC(=O)CN2C2=CC(C(=O)O)=CC=C2C=1C1CCCCC1 YVPUSKFBJNVTFX-UHFFFAOYSA-N 0.000 description 1
- IJCIPRKZMGOSQU-UHFFFAOYSA-N 14-cyclohexyl-3-methoxy-6-methyl-5,6,7,8-tetrahydroindolo[2,1-a][2,5]-benzodiazocine-11-carboxylic acid Chemical compound C12=CC=C(C(O)=O)C=C2N2CCN(C)CC3=CC(OC)=CC=C3C2=C1C1CCCCC1 IJCIPRKZMGOSQU-UHFFFAOYSA-N 0.000 description 1
- ANRDTJDAAYMYOE-UHFFFAOYSA-N 14-cyclohexyl-6-[2-(dimethylamino)ethyl]-3-methoxy-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid Chemical compound C12=CC=C(C(O)=O)C=C2N2CCN(CCN(C)C)CC3=CC(OC)=CC=C3C2=C1C1CCCCC1 ANRDTJDAAYMYOE-UHFFFAOYSA-N 0.000 description 1
- NCHXWGAACZWDTE-UHFFFAOYSA-N 14-cyclohexyl-6-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid Chemical compound C12=CC=CC=C2CN(CCN(C)C)CCN(C2=CC(=CC=C22)C(O)=O)C1=C2C1CCCCC1 NCHXWGAACZWDTE-UHFFFAOYSA-N 0.000 description 1
- OJSAUQMDYPYXPO-UHFFFAOYSA-N 14-cyclohexyl-6-[2-(dimethylamino)ethyl]-7-oxo-5,6,7,8-tetrahydroindolo[2,1-a][2.5]benzodiazocine-11-carboxylic acid Chemical compound C12=CC=C(C(O)=O)C=C2N2CC(=O)N(CCN(C)C)CC3=CC=CC=C3C2=C1C1CCCCC1 OJSAUQMDYPYXPO-UHFFFAOYSA-N 0.000 description 1
- NUQPORRFDWAOGN-UHFFFAOYSA-N 14-cyclohexyl-7-{[2-(dimethylamino)ethyl]amino}-7,8-dihydro-6h-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid Chemical compound C12=CC=C(C(O)=O)C=C2N2CC(NCCN(C)C)COC3=CC=CC=C3C2=C1C1CCCCC1 NUQPORRFDWAOGN-UHFFFAOYSA-N 0.000 description 1
- BBQVFZWAEDFOJE-UHFFFAOYSA-N 14-cyclohexyl-n-[(dimethylamino)sulfonyl]-3-methoxy-6-methyl-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxamide Chemical compound C12=CC=C(C(=O)NS(=O)(=O)N(C)C)C=C2N2CCN(C)CC3=CC(OC)=CC=C3C2=C1C1CCCCC1 BBQVFZWAEDFOJE-UHFFFAOYSA-N 0.000 description 1
- KLCVTCWOQDEUPQ-UHFFFAOYSA-N 15-cyclohexyl-6-[2-(dimethylamino)ethyl]-7-oxo-6,7,8,9-tetrahydro-5h-indolo[2,1-a][2,6]benzodiazonine-12-carboxylic acid Chemical compound C12=CC=C(C(O)=O)C=C2N2CCC(=O)N(CCN(C)C)CC3=CC=CC=C3C2=C1C1CCCCC1 KLCVTCWOQDEUPQ-UHFFFAOYSA-N 0.000 description 1
- DIPOAMJXBQWYQU-UHFFFAOYSA-N 19-cyclohexyl-10-oxo-9-(2-piperidin-1-ylethyl)-9,12-diazatetracyclo[10.7.0.02,7.013,18]nonadeca-1(19),2,4,6,13(18),14,16-heptaene-15-carboxylic acid Chemical compound C=12C3=CC=CC=C3CN(CCN3CCCCC3)C(=O)CN2C2=CC(C(=O)O)=CC=C2C=1C1CCCCC1 DIPOAMJXBQWYQU-UHFFFAOYSA-N 0.000 description 1
- SKDWJRKCMYHPMY-UHFFFAOYSA-N 19-cyclohexyl-9-[3-(dimethylamino)propyl]-10-oxo-9,12-diazatetracyclo[10.7.0.02,7.013,18]nonadeca-1(19),2,4,6,13(18),14,16-heptaene-15-carboxylic acid Chemical compound C12=CC=C(C(O)=O)C=C2N2CC(=O)N(CCCN(C)C)CC3=CC=CC=C3C2=C1C1CCCCC1 SKDWJRKCMYHPMY-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- RLFZYIUUQBHRNV-UHFFFAOYSA-N 2,5-dihydrooxadiazole Chemical compound C1ONN=C1 RLFZYIUUQBHRNV-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- NVKAMPJSWMHVDK-GITKWUPZSA-N 2-amino-9-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-3h-purin-6-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(N)=NC(O)=C2N=C1 NVKAMPJSWMHVDK-GITKWUPZSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- WFULTSRFOQKYER-UHFFFAOYSA-N 20-cyclohexyl-11-oxo-10,13-diazatetracyclo[11.7.0.02,7.014,19]icosa-1(20),2,4,6,14(19),15,17-heptaene-16-carboxylic acid Chemical compound C=12C3=CC=CC=C3CCNC(=O)CN2C2=CC(C(=O)O)=CC=C2C=1C1CCCCC1 WFULTSRFOQKYER-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- ZLEKHXKRTXDDJS-UHFFFAOYSA-N 3-cyclohexyl-9-(2-morpholin-4-ylethyl)-10-oxo-9,12-diazatetracyclo[10.7.0.02,7.013,18]nonadeca-1(19),2(7),3,5,13(18),14,16-heptaene-15-carboxylic acid Chemical compound C1(CCCCC1)C1=CC=CC=2CN(C(CN3C(C=21)=CC=1C=CC(=CC=13)C(=O)O)=O)CCN1CCOCC1 ZLEKHXKRTXDDJS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PPUDLEUZKVJXSZ-VPCXQMTMSA-N 4-amino-1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 PPUDLEUZKVJXSZ-VPCXQMTMSA-N 0.000 description 1
- NYPIRLYMDJMKGW-VPCXQMTMSA-N 4-amino-1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one Chemical compound C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 NYPIRLYMDJMKGW-VPCXQMTMSA-N 0.000 description 1
- ODLGMSQBFONGNG-JVZYCSMKSA-N 4-amino-1-[(2r,3r,4s,5r)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@](CO)(N=[N+]=[N-])O1 ODLGMSQBFONGNG-JVZYCSMKSA-N 0.000 description 1
- SLIMBESOHKKEQI-NCGUTPBLSA-N 4-amino-7-[(2r,3r,4r,5r)-3,4-diacetyloxy-5-(acetyloxymethyl)-3-methyloxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carboxylic acid Chemical compound CC(=O)O[C@]1(C)[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2C(C(O)=O)=C1 SLIMBESOHKKEQI-NCGUTPBLSA-N 0.000 description 1
- DUDRTIFDZYRYGJ-NHULRPGXSA-N 4-amino-7-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C(C#N)=C1 DUDRTIFDZYRYGJ-NHULRPGXSA-N 0.000 description 1
- CBWBJFJMNBPWAL-UHFFFAOYSA-N 4-chloro-5-iodo-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(I)=CN2 CBWBJFJMNBPWAL-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- WTDWVLJJJOTABN-UHFFFAOYSA-N 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide Chemical compound C1=C2C(C(=O)NC)=C(C=3C=CC(F)=CC=3)OC2=CC(N(CCO)S(C)(=O)=O)=C1C1CC1 WTDWVLJJJOTABN-UHFFFAOYSA-N 0.000 description 1
- 108091027075 5S-rRNA precursor Proteins 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KKEJRUSNFFVAHD-UHFFFAOYSA-N C12=CC=C(C(=O)NS(=O)(=O)N(C)C)C=C2N2CC(=O)N(CCN(C)C)CC3=CC=CC=C3C2=C1C1CCCCC1 Chemical compound C12=CC=C(C(=O)NS(=O)(=O)N(C)C)C=C2N2CC(=O)N(CCN(C)C)CC3=CC=CC=C3C2=C1C1CCCCC1 KKEJRUSNFFVAHD-UHFFFAOYSA-N 0.000 description 1
- TWDSCJUSRVOTOG-UHFFFAOYSA-N C12=CC=C(C(O)=O)C=C2N2CC(=O)N(CCN(C)C)CC3=CC=CC=C3C2=C1C1CCCC1 Chemical compound C12=CC=C(C(O)=O)C=C2N2CC(=O)N(CCN(C)C)CC3=CC=CC=C3C2=C1C1CCCC1 TWDSCJUSRVOTOG-UHFFFAOYSA-N 0.000 description 1
- AWNAJDMPVVNAKN-UHFFFAOYSA-N C12=CC=CC=C2CN(CCN(C)C)CCN(C2=CC(=CC=C22)C(O)=O)C1=C2C1CCCC1 Chemical compound C12=CC=CC=C2CN(CCN(C)C)CCN(C2=CC(=CC=C22)C(O)=O)C1=C2C1CCCC1 AWNAJDMPVVNAKN-UHFFFAOYSA-N 0.000 description 1
- AXPZRIPUENWNAX-UHFFFAOYSA-N C1CN(C)CCC1N1C(=O)CN2C3=CC(C(O)=O)=CC=C3C(C3CCCCC3)=C2C2=CC=CC=C2C1 Chemical compound C1CN(C)CCC1N1C(=O)CN2C3=CC(C(O)=O)=CC=C3C(C3CCCCC3)=C2C2=CC=CC=C2C1 AXPZRIPUENWNAX-UHFFFAOYSA-N 0.000 description 1
- RLPMOCZDQWWJNB-UHFFFAOYSA-N C=12C3=CC=CC=C3CN(CCN3CCCCC3)C(=O)CN2C2=CC(C(=O)NS(=O)(=O)N(C)C)=CC=C2C=1C1CCCCC1 Chemical compound C=12C3=CC=CC=C3CN(CCN3CCCCC3)C(=O)CN2C2=CC(C(=O)NS(=O)(=O)N(C)C)=CC=C2C=1C1CCCCC1 RLPMOCZDQWWJNB-UHFFFAOYSA-N 0.000 description 1
- CSCQZJJZTVSGBT-UHFFFAOYSA-N C=12C3=CC=CC=C3CNCCN2C2=CC(C(=O)O)=CC=C2C=1C1CCCCC1 Chemical compound C=12C3=CC=CC=C3CNCCN2C2=CC(C(=O)O)=CC=C2C=1C1CCCCC1 CSCQZJJZTVSGBT-UHFFFAOYSA-N 0.000 description 1
- IHHGMSVSVITDBB-KASLGQFXSA-N CCOC([C@H](C)NP(OC[C@H]([C@H]([C@@]1(C)O)O)OC1[n]1c2ncnc(N)c2c(-c2ncc[o]2)c1)(Oc1ccccc1)=O)=O Chemical compound CCOC([C@H](C)NP(OC[C@H]([C@H]([C@@]1(C)O)O)OC1[n]1c2ncnc(N)c2c(-c2ncc[o]2)c1)(Oc1ccccc1)=O)=O IHHGMSVSVITDBB-KASLGQFXSA-N 0.000 description 1
- BRXWRPCKVIKARN-WLOUWNNFSA-N C[C@@]1(C([n]2c3ncnc(N)c3c(-c3c[n](C)nn3)c2)O[C@H](CO)[C@H]1O)O Chemical compound C[C@@]1(C([n]2c3ncnc(N)c3c(-c3c[n](C)nn3)c2)O[C@H](CO)[C@H]1O)O BRXWRPCKVIKARN-WLOUWNNFSA-N 0.000 description 1
- ZTVITMOPWSQHOC-ZWRHBKRTSA-N C[C@@]1(C([n]2c3ncnc(N)c3c(-c3ncccn3)c2)OC(CO)[C@H]1O)O Chemical compound C[C@@]1(C([n]2c3ncnc(N)c3c(-c3ncccn3)c2)OC(CO)[C@H]1O)O ZTVITMOPWSQHOC-ZWRHBKRTSA-N 0.000 description 1
- BZWMWQFIWRMQMN-UIQZMBSCSA-N C[C@@]1([C@H]([n]2c3ncnc(N)c3c(-c3ncccn3)c2)OC(COP(O)(OP(O)(OP(O)(O)=O)=O)=O)[C@H]1O)O Chemical compound C[C@@]1([C@H]([n]2c3ncnc(N)c3c(-c3ncccn3)c2)OC(COP(O)(OP(O)(OP(O)(O)=O)=O)=O)[C@H]1O)O BZWMWQFIWRMQMN-UIQZMBSCSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940124683 HCV polymerase inhibitor Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- BZORFPDSXLZWJF-UHFFFAOYSA-N N,N-dimethyl-1,4-phenylenediamine Chemical compound CN(C)C1=CC=C(N)C=C1 BZORFPDSXLZWJF-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101710144128 Non-structural protein 2 Proteins 0.000 description 1
- 101800001020 Non-structural protein 4A Proteins 0.000 description 1
- 101800001019 Non-structural protein 4B Proteins 0.000 description 1
- 101800001014 Non-structural protein 5A Proteins 0.000 description 1
- 101710199667 Nuclear export protein Proteins 0.000 description 1
- VRTFXWLTSSBLIT-RJECSAPTSA-N OC(=O)C(F)(F)F.N1=NN(C)C=C1C(C1=C(N)N=CN=C11)=CN1[C@H]1[C@@](O)(C)[C@H](O)[C@@H](CO)O1 Chemical compound OC(=O)C(F)(F)F.N1=NN(C)C=C1C(C1=C(N)N=CN=C11)=CN1[C@H]1[C@@](O)(C)[C@H](O)[C@@H](CO)O1 VRTFXWLTSSBLIT-RJECSAPTSA-N 0.000 description 1
- SAZYNIADZISEDC-LSBNXPHQSA-N OC(=O)C(F)(F)F.S1C(OC)=NC(C=2C3=C(N)N=CN=C3N([C@H]3[C@]([C@H](O)[C@@H](CO)O3)(C)O)C=2)=C1 Chemical compound OC(=O)C(F)(F)F.S1C(OC)=NC(C=2C3=C(N)N=CN=C3N([C@H]3[C@]([C@H](O)[C@@H](CO)O3)(C)O)C=2)=C1 SAZYNIADZISEDC-LSBNXPHQSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 244000078856 Prunus padus Species 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108010068504 SCH6 Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 229940123627 Viral replication inhibitor Drugs 0.000 description 1
- 206010057293 West Nile viral infection Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LMRZAUJTVBTCFY-BDQIEHDPSA-N [(2r,3r,4r,5r)-3,4-diacetyloxy-5-[4-amino-5-[[(2-methylpropan-2-yl)oxycarbonylamino]carbamoyl]pyrrolo[2,3-d]pyrimidin-7-yl]-4-methyloxolan-2-yl]methyl acetate Chemical compound CC(=O)O[C@]1(C)[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2C(C(=O)NNC(=O)OC(C)(C)C)=C1 LMRZAUJTVBTCFY-BDQIEHDPSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229960000517 boceprevir Drugs 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbamic acid group Chemical group C(N)(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- BVUPAXXDXVQPHK-UHFFFAOYSA-N chembl520271 Chemical compound C12=CC=C(C(O)=O)C=C2N2CC(=O)N(C)CC3=CC=CC=C3C2=C1C1CCCCC1 BVUPAXXDXVQPHK-UHFFFAOYSA-N 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- ITVPBBDAZKBMRP-UHFFFAOYSA-N chloro-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound OP(O)(Cl)=O ITVPBBDAZKBMRP-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- PJZPDFUUXKKDNB-KNINVFKUSA-N ciluprevir Chemical compound N([C@@H]1C(=O)N2[C@H](C(N[C@@]3(C[C@H]3\C=C/CCCCC1)C(O)=O)=O)C[C@H](C2)OC=1C2=CC=C(C=C2N=C(C=1)C=1N=C(NC(C)C)SC=1)OC)C(=O)OC1CCCC1 PJZPDFUUXKKDNB-KNINVFKUSA-N 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- HKBUFTCADGLKAS-UHFFFAOYSA-N diazonio(trimethylsilylmethyl)azanide Chemical compound C[Si](C)(C)C[N-][N+]#N HKBUFTCADGLKAS-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000003720 ethoxymethylidene group Chemical group [H]C(=*)OC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- JUINSXZKUKVTMD-UHFFFAOYSA-N hydrogen azide Chemical compound N=[N+]=[N-] JUINSXZKUKVTMD-UHFFFAOYSA-N 0.000 description 1
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229940090438 infergen Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 229940106366 pegintron Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000001394 phosphorus-31 nuclear magnetic resonance spectrum Methods 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000025223 poliovirus infection Diseases 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
- FREJAOSUHFGDBW-UHFFFAOYSA-N pyrimidine-5-carbaldehyde Chemical compound O=CC1=CN=CN=C1 FREJAOSUHFGDBW-UHFFFAOYSA-N 0.000 description 1
- KYPREUXQEYJYPR-UHFFFAOYSA-N pyrimidine-5-carboximidamide Chemical compound NC(=N)C1=CN=CN=C1 KYPREUXQEYJYPR-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- WTFFOOAJSDVASL-UHFFFAOYSA-N tributyl(pyrimidin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=NC=CC=N1 WTFFOOAJSDVASL-UHFFFAOYSA-N 0.000 description 1
- JCZRGWAGRPABLT-UHFFFAOYSA-N tributyl-(2-methoxy-1,3-thiazol-4-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CSC(OC)=N1 JCZRGWAGRPABLT-UHFFFAOYSA-N 0.000 description 1
- JKVRTUCVPZTEQZ-UHFFFAOYSA-N tributyltin azide Chemical compound CCCC[Sn](CCCC)(CCCC)N=[N+]=[N-] JKVRTUCVPZTEQZ-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Xはヌクレオシド及びヌクレオチドアナログに存在する任意に置換された塩基環系であり、Xは塩基環系のN原子を介して糖鎖環と結合しており;
Zは1から3個のヘテロ原子を含み、任意にオキソ、S(O)n、S(O)nR4、C1−4アルキル、C1−4ハロアルキル、CH2OR4、CO2R4、CONR4R5、NR4C(O)R5又はNR4R5基で置換された5又は6員複素環であり、ここで、R4及びR5は独立して水素及びC1−4アルキルから選択され、ZはXを糖鎖環と結合するN原子から2個の環原子であるXの環原子と結合しており;
R1は水素、ヒドロキシ、ハロ又は任意にフルオロで置換されたC1−6アルキルであり;
R2はヒドロキシ、ハロ、OMe,C1−C16アルキルカルボニル又は水素であり;
R3は水素又は任意にフルオロで置換されたアジド、エチニル、シアノもしくはC1−6脂肪族基であり;
Q1は水素、一、二もしくは三リン酸基又は保護基Q3であり;
Q2は水素又は保護基Q4である。
R8は水素又はメチルであり;
あるいはR7とR8はそれらが結合している炭素原子と共に3から6員の脂肪族スピロ環系を形成し;
R9はアリール、アリールアルキル、ヘテロアリール又は
R10はヒドロキシ又はOR16基であり、ここで、R16はCH2OC(O)R17又はCH2CH2SR17であり、ここで、R17は任意にヒドロキシル基で置換されたC1−6アルキルカルボニルであり、あるいはR16は(CH2)2−4−O−(CH2)1−17CH3又はフェニル、ナフチル、ピリジニル、ピリミジニル、ピラジニル、ピリダジニル、インドリル、キノリニル又はイソキノリニルから選択される芳香環であり、前記芳香環は独立してハロゲン、C1−4アルキル、C1−4アルコキシ、C1−4アルキルチオ、シアノ、ニトロ、アミノ、カルボキシ、トリフルオロメチル、トリフルオロメトキシ、C1−4アルキルアミノ、ジ(C1−4アルキル)アミノ、C1−4アルキルカルボニル、C1−4アルキルカルボニルオキシ及びC1−4アルキルオキシカルボニルから構成される群から選択される1から5個の置換基で任意に置換されており、あるいはR10とQ4は結合を形成し、環状リン酸基を形成し;
R12はC6−16アルキル、C2−20アルケニル、(CH2)0−2C7−9シクロアルキル、(CH2)0−2C3−9シクロアルケニル、OC1−6アルキル又はアダマンチルであり;
R13及びR14は独立して水素及びC1−6アルキルから選択され;
あるいはR13とRl4はそれらが結合している炭素原子と共に3から6員の脂肪族スピロ環系を形成し;
及び/又はQ4はメチル、C1−16アルキルカルボニル、C2−18アルケニルカルボニル、C1−10アルキルオキシカルボニル、C3−6シクロアルキルカルボニル、C3−6シクロアルキルオキシカルボニル及び構造式:
5−(2−メトキシ−1,3−チアゾール−4−イル)−7−(2−C−メチル−β−D−リボフラノシル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−ピリミジン−2−イル−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(1H−ピラゾール−4−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(1,2,4−オキサジアゾール−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(1−メチル−1H−1,2,3−トリアゾール−4−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(2−チエニル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1−メチル−1H−テトラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(2−メチル−2H−テトラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
5−(2−メトキシ−1,3−チアゾール−4−イル)−7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1H−ピラゾール−4−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,2,4−オキサジアゾール−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1−メチル−1H−1,2,3−トリアゾール−4−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−デオキシ−2−フルオロ−2−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−デオキシ−2−フルオロ−2−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−ピリミジン−2−イル−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−デオキシ−2−フルオロ−2−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,2,4−オキサジアゾール−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−デオキシ−2−フルオロ−2−メチル−β−D−リボフラノシル)−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(6−メトキシピリジン−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−デオキシ−2−フルオロ−2−メチル−β−D−リボフラノシル)−5−(1,2,4−オキサジアゾール−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−デオキシ−2−フルオロ−2−メチル−β−D−リボフラノシル)−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
1−(2−C−メチル−β−D−リボフラノシル)−3−(1H−ピラゾール−3−イル)−1H−ピラゾロ[3,4−d]ピリミジン−4−アミン、
1−[5−O−(ヒドロキシ{[ヒドロキシ(ホスホノオキシ)ホスホリル]オキシ}ホスホリル)−2−C−メチル−β−D−リボフラノシル]−3−(1H−ピラゾール−3−イル)−1H−ピラゾロ[3,4−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(1,3,4−オキサジアゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,3,4−オキサジアゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
2−{[(R)−({(2R,3S,4R,5R)−5−[4−アミノ−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−7−イル]−3,4−ジヒドロキシ−4−メチルテトラヒドロフラン−2−イル}メトキシ)(フェノキシ)ホスホリル]アミノ}プロパン酸エチル、
2−{[(R)−({(2R,3S,4R,5R)−5−[4−アミノ−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−7−イル]−3,4−ジヒドロキシ−4−メチルテトラヒドロフラン−2−イル}メトキシ)(フェノキシ)ホスホリル]アミノ}プロパン酸エチル
及びその医薬的に許容可能な塩が挙げられる。
全溶媒は市販品とし、それ以上精製せずに使用した。日常的な脱保護段階とカップリング段階を除き、反応はオーブン乾燥(110℃)したガラス容器で窒素雰囲気下に実施した。有機抽出層を硫酸ナトリウムで乾燥し、(乾燥剤の濾過後に)減圧下にロータリーエバポレーターで濃縮した。フラッシュクロマトグラフィーは公開手順(W.C.Still et al.,J.Org.Chem.,43:2923)に従ってシリカゲルで実施するか、又はプレパックカラムを利用する半自動フラッシュクロマトグラフィーシステムで実施した。
AcOH:酢酸;aq.:水溶液;bs:広幅一重線;bt:広幅三重線;DBU:1,8−ジアザビシクロ[5.4.0]ウンデカ−7−エン;DIAD:アゾジカルボン酸ジイソプロピル;DIPEA:ジイソプロピルエチルアミン;DMF:ジメチルホルムアミド;DMSO:ジメチルスルホキシド;eq.:当量;Et2O:ジエチルエーテル;EtOAc:酢酸エチル;EtOH:エタノール;(HNBu3)2H2P2O7:ピロリン酸ビストリブチルアンモニウム;h:時間;M:モル;MeCN:アセトニトリル;MeOH:メタノール;(MeO)3PO:リン酸トリメチル;min:分;NaBH3CN:シアノ水素化ホウ素ナトリウム;NBu3:トリブチルアミン;NMP:1−メチル−2−ピロリジノン;Pd(PPh3)4:テトラキス(トリフェニルホスフィン)パラジウム(0);PE:石油エーテル;P(O)Cl3:オキシ塩化リン;RP−HPLC:逆相高性能液体クロマトグラフィー;RT:室温;SPE:固相抽出;TBDMS:tert−ブチルジメチルシリル;TEA:トリエチルアミン;TFA:トリフルオロ酢酸;THF:テトラヒドロフラン。
0℃又は室温で(シーブ上に保存しておいた)リン酸トリメチルに(ピリジンとトルエンの共蒸発により予め乾燥しておいた)適切なヌクレオシドを溶解した0.15M溶液に原液POCl3(2.5eq)をシリンジで滴下した。得られた混合物を2時間0℃又は室温で撹拌後、ピロリン酸ビストリブチルアンモニウム(6.0eq)とトリブチルアミン(5.0eq)のDMF中0.5M溶液を反応混合物に激しい撹拌下に一度に加えた。1分間0℃又は室温で激しく撹拌後、炭酸水素トリエチルアンモニウムバッファー(1M水溶液,50eq,pH=7.5)を反応混合物に加えた後、更に3時間室温で撹拌し、減圧濃縮した(冷浴)。残渣を水に溶解し、0.5M TEAB(pH=7.5)のバッファー系とのアニオン交換SPE後にRP−HPLC精製(移動相:5mM重炭酸ジメチルヘキシルアンモニウム,pH=8.0/MeCN)により三リン酸エステルを回収し、標記化合物をトリスジメチルヘキシルアンモニウム塩(油状物)として得た。典型的な収率は2%から40%であった。
本発明の化合物の細胞毒性と抗ウイルス特異性も以下のカウンタースクリーニングで評価した。
7−(2−C−メチル−β−D−リボフラノシル)−5−(1−メチル−1H−テトラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン(A)及び7−(2−C−メチル−β−D−リボフラノシル)−5−(2−メチル−2H−テトラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン(B)
4−アミノ−7−(2−C−メチル−β−D−リボフラノシル)−7H−ピロロ[2,3−d]ピリミジン−5−カルボニトリル(Ding Y.et al.,Bioorganic and Medicinal Chemistry Letters 2005,15,725)をトルエンとDMFの6:1 v:v混液に溶解した0.15M溶液にアジドトリブチル錫(6eq)を加え、得られた混合物を30分間マイクロ波照射下で130℃に加熱した。溶液を室温まで冷却し、HClのMeOH中1.25M溶液で希釈し、減圧濃縮した。MeCN/水+0.1% TFAを溶離液として残渣を分取RP−HPLCにより精製し、標記化合物を固体として得た(77%)。1H NMR(300MHz,DMSO−d6)δ8.38(s,1H),8.28(s,1H),6.27(s,1H),3.98(m,1H),3.93−3.84(m,2H),3.78(m,1H),0.80(s,3H);MS(ES+)C13H16N8O4計算値:348,実測値:349[M+H]+。
ステップAからの7−(2−C−メチル−β−D−リボフラノシル)−5−(1H−テトラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミンとK2CO3(1.05eq)をアセトンとDMFの1:1 v:v混液に溶解した0.1M溶液にヨードメタン(2.0eq)を加えた。得られた混合物を室温で3時間撹拌し、HClのMeOH中1.25M溶液で希釈し、揮発分を減圧除去した。MeCN/水+0.1% TFAを溶離液として残渣を分取RP−HPLCにより精製し、標記生成物A及びBを2:1混合物の固体として得た(22%)。1H NMR(300MHz,DMSO−d6)δ8.77(s,1HB),8.65(s,1HA)8.38(s,1HA),8.36(s,1HB),6.27(s,1HB),6.25(s,1HA),4.46(s,3HA),4.25(s,3HB),4.14(d,J=9.0Hz,1HB),4.04(d,J=9.0Hz,1HA),4.01−3.83(m,2HA+B),3.80−3.65(m,1HA+B),0.80(s,3HB),0.76(s,3HA);MS(ES+)C14H18N8O4計算値:362,実測値:363[M+H]+。
7−(2−C−メチル−β−D−リボフラノシル)−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
7−(2−C−メチル−β−D−リボフラノシル)−5−ピリミジン−2−イル−7H−ピロロ[2,3−d]ピリミジン−4−アミン
7−(2−C−メチル−β−D−リボフラノシル)−5−(1,2,4−オキサジアゾール−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
7−(2−C−メチル−β−D−リボフラノシル)−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
5−(2−メトキシ−1,3−チアゾール−4−イル)−7−(2−C−メチル−β−D−リボフラノシル)−7H−ピロロ[2,3−d]ピリミジン−4−アミントリフルオロ酢酸塩
7−(2−C−メチル−β−D−リボフラノシル)−5−(1H−ピラゾール−4−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
7−(2−C−メチル−β−D−リボフラノシル)−5−(1−メチル−1H−1,2,3−トリアゾール−4−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミントリフルオロ酢酸塩
7−(2−デオキシ−2−フルオロ−2−メチル−β−D−リボフラノシル)−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
DIAD(2.8eq)をPh3P(3.0eq)のアセトニトリル中0.05M溶液に加え、得られた混合物を30分間0℃で撹拌した。次に溶液を4−クロロ−5−ヨード−7H−ピロロ[2,3−d]ピリミジン(2.2eq)と3,5−ジ−O−ベンゾイル−2−デオキシ−2−フルオロ−2−メチル−D−リボフラノース(1.0eq)のアセトニトリル中0.1M溶液に−40℃にてカニューレで加えた。得られた薄茶色懸濁液を室温で一晩撹拌した。反応混合物をAcOEtでクエンチし、有機相を水、ブラインで洗浄し、Na2SO4で乾燥した。揮発分を減圧除去し、残渣をフラッシュクロマトグラフィー(0%→5% AcOEt/ヘキサンから勾配溶出後、5% AcOEt/ヘキサンからアイソクラチック溶出)により精製し、4−クロロ−7−(3,5−ジ−O−ベンゾイル−2−デオキシ−2−フルオロ−2−メチル−β−D−リボフラノシル)−5−ヨード−7H−ピロロ[2,3−d]ピリミジンを最初に溶出するアノマーとして得た。これをNH3のMeOH(0.01M)中7M溶液に溶解し、得られた混合物を密閉容器にて一晩110℃で撹拌した。次に揮発分を減圧除去し、MeOH:DCM 1:9を溶離液として残渣をフラッシュクロマトグラフィーにより精製し、標記化合物を白色泡状物として得た(24%)。1H NMR(400MHz,CD3CN/D2O)δ8.14(s,1H),7.61(s,1H),6.35(d,J=18.5Hz,1H),4.20(dd,J=24.0,9.4Hz,1H),3.98−3.95(m,2H),3.78(dd,J=12.0,2.8Hz,1H),1.00(d,J=22.6Hz,3H);19F−NMR(400MHz,CD3CN/D2O)δ−160.89;MS(ES+)C12H14FIN4O3計算値:408,実測値:409(M+H+)。
5−ヨード−7−(2−C−メチル−β−D−リボフラノシル)−7H−ピロロ[2,3−d]ピリミジン−4−アミンの代わりに7−(2−デオキシ−2−フルオロ−2−メチル−β−D−リボフラノシル)−5−ヨード−7H−ピロロ[2,3−d]ピリミジン−4−アミンを使用し、実施例5に記載したと同一の手順に従い、標記化合物を得た(68%)。1H NMR(400MHz,CD3CN/D2O)δ8.19(bd,J=17.1Hz,2H),7.72(bs,1H),6.63(bs,1H),6.47(d,J=17.1Hz,1H),4.26(bd,J=25.1Hz,1H),4.05(bs,2H),3.87(m,1H),1.08(d,J=22.4Hz,3H);19F−NMR(400MHz,CD3CN/D2O)δ−162.64;MS(ES+)C15H17FN5O3計算値:348,実測値:349(M+H+)。
7−(2−デオキシ−2−フルオロ−2−メチル−β−D−リボフラノシル)−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
7−(2−デオキシ−2−フルオロ−2−メチル−β−D−リボフラノシル)−5−(1,2,4−オキサジアゾール−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1−メチル−1H−テトラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン及び7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(2−メチル−2H−テトラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
1H NMR(300MHz,D2O,300K)δ8.61−8.16(m,1HA+1HB),8.02(s,1HA),8.00(s,1HB),6.33(s,1HB),6.25(s,1HA),4.60(m,1HA or 1HB),4.55−4.39(m,1HA+1HB),4.38−4.27(m,1HA+1HB),4.17(m,1HA or 1HB),3.28−3.08(m,6H),3.05−2.76(m,18H),1.85−1.64(m,6H),1.50−1.25(m,18H),1.00−0.80(m,12H);31P NMR(121MHz,D2O,300K)δ−10.08−−11.26(m,2PA+2PB),−22.70−−23.56(m,1PA+1PB);MS(ES−)C14H21N8O13P3計算値:602.0,実測値:601[M−H]−,623[M+Na−H]−。
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−ピリミジン−2−イル−7H−ピロロ[2,3−d]ピリミジン−4−アミン
5−(2−メトキシ−1,3−チアゾール−4−イル)−7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1H−ピラゾール−4−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,2,4−オキサジアゾール−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
1H NMR(300MHz,D2O,300K)δ9.33(s,1H),8.41(m,1H),8.09(s,1H),6.23(s,1H),4.61(m,1H),4.55(m,1H),4.33(m,1H),4.16(d,J=9.4Hz,1H),3.17(m,6H),2.92(m,18H),1.82−1.68(m,6H),1.48−1.29(m,18H),0.98−0.87(m,9H),0.84(s,3H);31P NMR(121MHz,D2O,300K)δ−10.45−−11.15(m,2P),−22.92(t,J=19.6Hz,1P);MS(ES−)C14H19N6O14P3計算値:588.0,実測値:587[M−H]−。
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1−メチル−1H−1,2,3−トリアゾール−4−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
7−(2−デオキシ−2−フルオロ−2−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,2,4−オキサジアゾール−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
7−(2−デオキシ−2−フルオロ−2−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
7−(2−デオキシ−2−フルオロ−2−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
1−(2−C−メチル−β−D−リボフラノシル)−3−(1H−ピラゾール−3−イル)−1H−ピラゾロ[3,4−d]ピリミジン−4−アミン
1−[5−O−(ヒドロキシ{[ヒドロキシ(ホスホノオキシ)ホスホリル]オキシ}ホスホリル)−2−C−メチル−β−D−リボフラノシル]−3−(1H−ピラゾール−3−イル)−1H−ピラゾロ[3,4−d]ピリミジン−4−アミン
7−(2−C−メチル−β−D−リボフラノシル)−5−(1,3,4−オキサジアゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
2−メチル−2−ブテン(THF中2M,20eq)を加えたt−ブタノールに(Watanabe,S.et al.,Nucleosides and Nucleotides,1983,2,113及びSeela,F.et al.,Synthesis,1997,1067に報告されている手順に従って製造した)4−アミノ−7−(2,3,5−トリ−O−アセチル−2−C−メチル−β−D−リボフラノシル)−7H−ピロロ[2,3−d]ピリミジン−5−カルボアルデヒドを溶解した0.05M溶液に0℃で亜塩素酸ナトリウム(10eq)と一塩基性リン酸ナトリウム(7.5eq)の2.0M水溶液を滴下した。得られた反応混合物を室温で一晩撹拌した。揮発分を減圧除去し、残渣を水で希釈し、DCMで抽出した。有機層を合わせてブラインで洗浄し、Na2SO4で乾燥し、減圧下に濃縮乾涸した。DCM中0%→5% MeOHを溶離液として残渣をシリカゲルクロマトグラフィーにより精製し、標記化合物を白色固体として得た(90%)。1H NMR(300MHz,DMSO−d6)δ8.19(s,1H),8.00(s,1H),6.61(s,1H),5.53(d,J=6.4Hz,1H),4.48−4.32(m,3H),2.16−2.06(m,9H),1.33(s,3H);MS(ES+)C19H22N4O9計算値:450.4,実測値:451[M+H]+。
ヒドラジンカルボン酸tert−ブチル(1.0eq)と1H−ベンゾトリアゾール−1−オール水和物(2.0eq)を加えたTHFに4−アミノ−7−(2,3,5−トリ−O−アセチル−2−C−メチル−β−D−リボフラノシル)−7H−ピロロ[2,3−d]ピリミジン−5−カルボン酸を溶解した0.2M溶液を0℃に冷却し、撹拌下に4−メチルモルホリン(1.0eq)を加えた。0℃で5分間撹拌後、N,N’−ジシクロヘキシルカルボジイミド(1.0eq)を加えた。反応混合物を0℃で1時間、室温で12時間撹拌後、0℃まで冷却し、セライトのショートパッドで濾過した。濾液をDCMで希釈し、飽和NaHCO3水溶液、ブラインで洗浄し、Na2SO4で乾燥した。残渣を減圧下に蒸発乾涸し、4−アミノ−N’−(tert−ブトキシカルボニル)−7−(2,3,5−トリ−O−アセチル−2−C−メチル−β−D−リボフラノシル)−7H−ピロロ[2,3−d]ピリミジン−5−カルボヒドラジドをオフホワイト固体として得た。MS(ES+)C24H32N6O10計算値:564.65,実測値:565[M+H]+。
オルトギ酸トリエチル(2.0eq)を加えたDMFに4−アミノ−7−(2−C−メチル−β−D−リボフラノシル)−7H−ピロロ[2,3−d]ピリミジン−5−カルボヒドラジド(1.0eq)を溶解した0.5M溶液に撹拌下にBF3・Et2O(0.2eq)を滴下した。反応混合物を70℃に180分間加熱し、目的分子と7−[2,3−O−(エトキシメチリデン)−2−C−メチル−β−D−リボフラノシル]−5−(1,3,4−オキサジアゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン中間体の1:1混合物を得た。次に反応混合物を室温まで冷却し、水で希釈し、1M HCl水溶液でおよそpH2まで20分間処理後、6M NH4OH水溶液で(およそpH8まで)処理し、室温で30分間撹拌した。次に反応混合物を減圧蒸発させ、MeCN/水+0.1% TFAを溶離液として分取RP−HPLCにより精製し、標記化合物(25%)を白色綿毛状固体として得た。1H NMR(300MHz,DMSO−d6)δ9.34(s,1H),8.66(s,1H),8.31(s,1H),6.22(s,1H),4.17−3.82(m,3H),3.78−3.67(m,1H),0.78(s,3H);(MS(ES+)C14H16N6O5計算値348.31,実測値349[M+H]+。
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,3,4−オキサジアゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
2−{[(R)−({(2R,3S,4R,5R)−5−[4−アミノ−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−7−イル]−3,4−ジヒドロキシ−4−メチルテトラヒドロフラン−2−イル}メトキシ)(フェノキシ)ホスホリル]アミノ}プロパン酸エチル
2−{[(R)−({(2R,3S,4R,5R)−5−[4−アミノ−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−7−イル]−3,4−ジヒドロキシ−4−メチルテトラヒドロフラン−2−イル}メトキシ)(フェノキシ)ホスホリル]アミノ}プロパン酸エチル
HCV NS5BポリメラーゼとHCV複製の阻害を測定するために使用したアッセイについて以下に記載する。
本アッセイは本発明のヌクレオシド誘導体がヘテロマーRNA鋳型上のC型肝炎ウイルス(HCV)のRNA依存性RNAポリメラーゼ(NS5B)の酵素活性を阻害する能力を測定するために使用した。
アッセイバッファー条件:(合計52.5μL/反応)
−20mM Tris,pH7.5
−45mM KCl
−2mM MgCl2
−0.01% Triton X−100
−1μg BSA,DNase Free
−1mM DTT
−2nM DC55−1b.BK又は10nM DC55−2b.2
−20nM異種鋳型dCoh
−UTP 1uM
−ATP 1uM
−CTP 1uM
−GTP 1uM
−3H−UTP 1,000,000cpm
−H2O中の阻害剤化合物2.5μl/反応。
本発明の化合物がサブゲノムHCVレプリコンを含む培養肝癌(HuH−7)細胞中でC型肝炎ウイルスRNAの複製に作用する能力も評価した。アッセイの詳細を以下に記載する。このレプリコンアッセイはV.Lohmann,F.Korner,J−O.Koch,U.Herian,L.Theilmann,and R.Bartenschlager,“Replication of a Sub−genomic Hepatitis C Virus RNAs in a Hepatoma Cell Line,”Science 285:110(1999)に記載されているアッセイの変法である。
アッセイはin situリボヌクレアーゼ保護シンチレーション近接型プレートアッセイ(SPA)とした。96ウェルCytostarプレート(Amersham)で0.8mg/mL G418を添加した培地100〜200μLに細胞10,000〜40,000個を撒いた。0から18時間の時点で1%DMSO中100μMまでの各種濃度の化合物を細胞に添加後、24〜96時間培養した。細胞を固定し(20分,10%ホルマリン)、透過性にし(20分,0.25% Triton X−100/PBS)、RNAウイルスゲノムに含まれる(プラス)鎖NS5B(又は他の遺伝子)に相補的な1本鎖33P RNAプローブとハイブリダイズさせた(一晩,50℃)。細胞を洗浄し、RNAseで処理し、洗浄し、65℃まで加熱し、Top−Countで計数した。複製の阻害をカウント毎分(cpm)の低下として読取った。
本発明の化合物の経口組成物の1特定実施形態として、総量580から590mgを提供するために十分な微粉状ラクトースと実施例のいずれか1種の化合物50mgを配合し、サイズOハードゼラチンカプセルに充填する。
Claims (15)
- 構造式(I):
Xはヌクレオシド及びヌクレオチドアナログに存在する任意に置換された塩基環系であり、Xは塩基環系のN原子を介して糖鎖環と結合しており;
Zは1から3個のヘテロ原子を含み、任意にオキソ、S(O)n、S(O)nR4、C1−4アルキル、C1−4ハロアルキル、CH2OR4、CO2R4、CONR4R5、NR4C(O)R5又はNR4R5基で置換された5又は6員複素環であり、ここで、R4及びR5は独立して水素及びC1−4アルキルから選択され、ならびにZはXを糖鎖環と結合するN原子から2個の環原子であるXの環原子と結合しており;
R1は水素、ヒドロキシ、ハロ又は任意にフルオロで置換されたC1−6アルキルであり;
R2はヒドロキシ、ハロ、OMe,C1−C16アルキルカルボニル又は水素であり;
R3は水素又は任意にフルオロで置換されたアジド、エチニル、シアノもしくはC1−6脂肪族基であり;
Q1は水素、一、二もしくは三リン酸基又は保護基Q3であり;ならびに
Q2は水素又は保護基Q4である。]
の化合物及びその医薬的に許容可能な塩。 - Xが任意にハロ、1個以上のオキソもしくはヒドロキシ基、又は任意にCOR6(R6はC1−6脂肪族基又はフェニルである。)で置換された1個以上のアミノ基で置換されたプリン、ピロロピリミジン、ピラゾロピリミジン又はピリミジン環である請求項1に記載の化合物。
- Zが酸素及び窒素から選択される2又は3個のヘテロ原子を含む5員複素環であり、前記ヘテロ原子の最大1個が酸素である請求項1又は2に記載の化合物。
- R1がメチル又はフッ素であり、R2がヒドロキシ又はフルオロであり、ならびにR3が水素である請求項1から3のいずれか一項に記載の化合物。
- Q1が水素又はトリホスホリルである請求項1から5のいずれか一項に記載の化合物。
- 化合物が、
5−(2−メトキシ−1,3−チアゾール−4−イル)−7−(2−C−メチル−β−D−リボフラノシル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−ピリミジン−2−イル−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(1H−ピラゾール−4−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(1,2,4−オキサジアゾール−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(1−メチル−1H−1,2,3−トリアゾール−4−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(2−チエニル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1−メチル−1H−テトラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(2−メチル−2H−テトラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
5−(2−メトキシ−1,3−チアゾール−4−イル)−7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1H−ピラゾール−4−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,2,4−オキサジアゾール−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1−メチル−1H−1,2,3−トリアゾール−4−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−デオキシ−2−フルオロ−2−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−デオキシ−2−フルオロ−2−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−ピリミジン−2−イル−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−デオキシ−2−フルオロ−2−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,2,4−オキサジアゾール−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−デオキシ−2−フルオロ−2−メチル−β−D−リボフラノシル)−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(6−メトキシピリジン−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−デオキシ−2−フルオロ−2−メチル−β−D−リボフラノシル)−5−(1,2,4−オキサジアゾール−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−デオキシ−2−フルオロ−2−メチル−β−D−リボフラノシル)−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
1−(2−C−メチル−β−D−リボフラノシル)−3−(1H−ピラゾール−3−イル)−1H−ピラゾロ[3,4−d]ピリミジン−4−アミン、
1−[5−O−(ヒドロキシ{[ヒドロキシ(ホスホノオキシ)ホスホリル]オキシ}ホスホリル)−2−C−メチル− −D−リボフラノシル]−3−(1H−ピラゾール−3−イル)−1H−ピラゾロ[3,4−d]ピリミジン−4−アミン、
7−(2−C−メチル−β−D−リボフラノシル)−5−(1,3,4−オキサジアゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
7−(2−C−メチル−5−トリホスホ−β−D−リボフラノシル)−5−(1,3,4−オキサジアゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン、
2−{[(R)−({(2R,3S,4R,5R)−5−[4−アミノ−5−(1H−ピラゾール−5−イル)−7H−ピロロ[2,3−d]ピリミジン−7−イル]−3,4−ジヒドロキシ−4−メチルテトラヒドロフラン−2−イル}メトキシ)(フェノキシ)ホスホリル]アミノ}プロパン酸エチル、
2−{[(R)−({(2R,3S,4R,5R)−5−[4−アミノ−5−(1,3−オキサゾール−2−イル)−7H−ピロロ[2,3−d]ピリミジン−7−イル]−3,4−ジヒドロキシ−4−メチルテトラヒドロフラン−2−イル}メトキシ)(フェノキシ)ホスホリル]アミノ}プロパン酸エチル
から選択される請求項1から8のいずれか一項に記載の化合物及びその医薬的に許容可能な塩。 - 医薬的に許容可能な担体と共に請求項1から8のいずれか一項に記載の化合物を含有する医薬組成物。
- 医薬用としての請求項1から8のいずれか一項に記載の化合物。
- HCV感染症の治療又は予防用としての請求項1から8のいずれか一項に記載の化合物。
- HCV感染症の治療又は予防用医薬の製造における請求項1から8のいずれか一項に記載の化合物の使用。
- 有効量の請求項1から8のいずれか一項に記載の化合物によりHCV NS5Bポリメラーゼを阻害する、HCV複製を阻害する又はHCV感染症を治療する方法。
- 請求項1から8のいずれか一項に記載の化合物とHCV感染症を治療するために有用な1種以上の作用剤を併用して、有効量の本発明の化合物によりHCV NS5Bポリメラーゼを阻害する、HCV複製を阻害する又はHCV感染症を治療する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0815968.3A GB0815968D0 (en) | 2008-09-03 | 2008-09-03 | Antiviral agents |
GB0815968.3 | 2008-09-03 | ||
PCT/EP2009/061330 WO2010026153A1 (en) | 2008-09-03 | 2009-09-02 | Nucleoside derivatives as inhibitors of viral polymerases |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2012501999A true JP2012501999A (ja) | 2012-01-26 |
Family
ID=39866122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011525532A Pending JP2012501999A (ja) | 2008-09-03 | 2009-09-02 | ウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20110306573A1 (ja) |
EP (1) | EP2324043A1 (ja) |
JP (1) | JP2012501999A (ja) |
AU (1) | AU2009289265A1 (ja) |
CA (1) | CA2735783A1 (ja) |
GB (1) | GB0815968D0 (ja) |
WO (1) | WO2010026153A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012524731A (ja) * | 2009-04-22 | 2012-10-18 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー, アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック | 治療的使用のための新規7−デアザプリンヌクレオシド |
JP2015510946A (ja) * | 2012-03-21 | 2015-04-13 | アリオス バイオファーマ インク. | 置換されたヌクレオシド、ヌクレオチドおよびそのアナログ |
US10464965B2 (en) | 2011-12-22 | 2019-11-05 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US10485815B2 (en) | 2012-03-21 | 2019-11-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CN101099745A (zh) | 2000-05-26 | 2008-01-09 | 艾登尼科斯(开曼)有限公司 | 处理黄病毒和瘟病毒的方法和组合物 |
RU2005118421A (ru) | 2002-11-15 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | 2'-разветвленные нуклеозиды и мутация flaviviridae |
EP2619215B1 (en) | 2010-09-22 | 2018-09-05 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
JP2014514295A (ja) | 2011-03-31 | 2014-06-19 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
TW201329096A (zh) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
EP2852605B1 (en) | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphate prodrugs for hcv infection |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
MD20140134A2 (ro) | 2012-05-22 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice |
US9422323B2 (en) | 2012-05-25 | 2016-08-23 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
MX353422B (es) | 2012-10-08 | 2018-01-12 | Idenix Pharmaceuticals Llc | Análogos de 2'-cloronucleósido para infección por vhc. |
EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
SI2935303T1 (sl) | 2012-12-21 | 2021-08-31 | Janssen Biopharma, Inc. | 4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV |
WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
WO2014169280A2 (en) | 2013-04-12 | 2014-10-16 | Achillion Pharmaceuticals, Inc. | Deuterated nucleoside prodrugs useful for treating hcv |
US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
US20150037282A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
EA201690526A1 (ru) | 2013-10-11 | 2017-02-28 | Алиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
EP3131914B1 (en) | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
US10953029B2 (en) | 2015-09-23 | 2021-03-23 | Merck Sharp & Dohme Corp. | 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof |
US11040975B2 (en) | 2017-12-08 | 2021-06-22 | Merck Sharp & Dohme Corp. | Carbocyclic nucleoside reverse transcriptase inhibitors |
US12030903B2 (en) | 2020-02-18 | 2024-07-09 | Gilead Sciences, Inc. | Antiviral compounds |
TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
JP2024512771A (ja) | 2021-04-16 | 2024-03-19 | ギリアード サイエンシーズ, インコーポレイテッド | アミドを使用してカルバヌクレオシドを調製する方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03504969A (ja) * | 1988-06-10 | 1991-10-31 | メデイヴイル・アクチエボラーグ | ピリミジン誘導体 |
WO1994017803A1 (en) * | 1993-02-03 | 1994-08-18 | Gensia, Inc. | Adenosine kinase inhibitors |
JP2005530759A (ja) * | 2002-05-06 | 2005-10-13 | ジェネラブズ テクノロジーズ インコーポレーティッド | C型肝炎ウイルス感染症を治療するためのヌクレオシド誘導体 |
JP2006505537A (ja) * | 2002-09-30 | 2006-02-16 | ジェネラブス テクノロジーズ,インコーポレイテッド | C型肝炎ウイルスの感染を治療するためのヌクレオシド誘導体 |
WO2008067002A2 (en) * | 2006-09-11 | 2008-06-05 | Southern Research Institute | Azole nucleosides and use as inhibitors of rna and dna varial polymerases |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1223831A (en) * | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
-
2008
- 2008-09-03 GB GBGB0815968.3A patent/GB0815968D0/en not_active Ceased
-
2009
- 2009-09-02 WO PCT/EP2009/061330 patent/WO2010026153A1/en active Application Filing
- 2009-09-02 AU AU2009289265A patent/AU2009289265A1/en not_active Abandoned
- 2009-09-02 JP JP2011525532A patent/JP2012501999A/ja active Pending
- 2009-09-02 EP EP09782502A patent/EP2324043A1/en not_active Withdrawn
- 2009-09-02 CA CA2735783A patent/CA2735783A1/en not_active Abandoned
- 2009-09-02 US US13/061,746 patent/US20110306573A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03504969A (ja) * | 1988-06-10 | 1991-10-31 | メデイヴイル・アクチエボラーグ | ピリミジン誘導体 |
WO1994017803A1 (en) * | 1993-02-03 | 1994-08-18 | Gensia, Inc. | Adenosine kinase inhibitors |
JP2005530759A (ja) * | 2002-05-06 | 2005-10-13 | ジェネラブズ テクノロジーズ インコーポレーティッド | C型肝炎ウイルス感染症を治療するためのヌクレオシド誘導体 |
JP2006505537A (ja) * | 2002-09-30 | 2006-02-16 | ジェネラブス テクノロジーズ,インコーポレイテッド | C型肝炎ウイルスの感染を治療するためのヌクレオシド誘導体 |
WO2008067002A2 (en) * | 2006-09-11 | 2008-06-05 | Southern Research Institute | Azole nucleosides and use as inhibitors of rna and dna varial polymerases |
Non-Patent Citations (1)
Title |
---|
JPN5012003365; SCHRAM, KARL H.: 'PYRROLOPYRIMIDINE NUCLEOSIDES VIII. SYNTHESIS OF SANGIVAMYCIN DERIVATIVES 以下備考' JOURNAL OF CARBOHYDRATES. NUCLEOSIDES. NUCLEOTIDES V1 N1, 1974, P39-54 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012524731A (ja) * | 2009-04-22 | 2012-10-18 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー, アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック | 治療的使用のための新規7−デアザプリンヌクレオシド |
JP2015013901A (ja) * | 2009-04-22 | 2015-01-22 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー, アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック | 治療的使用のための新規7−デアザプリンヌクレオシド |
US10464965B2 (en) | 2011-12-22 | 2019-11-05 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US11021509B2 (en) | 2011-12-22 | 2021-06-01 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
JP2015510946A (ja) * | 2012-03-21 | 2015-04-13 | アリオス バイオファーマ インク. | 置換されたヌクレオシド、ヌクレオチドおよびそのアナログ |
US10485815B2 (en) | 2012-03-21 | 2019-11-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2010026153A1 (en) | 2010-03-11 |
CA2735783A1 (en) | 2010-03-11 |
US20110306573A1 (en) | 2011-12-15 |
AU2009289265A1 (en) | 2010-03-11 |
GB0815968D0 (en) | 2008-10-08 |
EP2324043A1 (en) | 2011-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012501999A (ja) | ウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体 | |
JP2012517401A (ja) | 抗ウィルス薬 | |
US8071568B2 (en) | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection | |
US7879815B2 (en) | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection | |
AU2005267421B2 (en) | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection | |
US8148349B2 (en) | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection | |
US7632821B2 (en) | Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection | |
US20100152128A1 (en) | Antiviral Agents | |
BG108000A (bg) | Н"кл...озидни производни, използвани ка'о инхиби'ори на зави'има о' рнк, рнк вир"'на полим...раза | |
WO2015101183A1 (zh) | 尿嘧啶核苷酸类似物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20120705 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120709 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20120727 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140121 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140701 |